NBIX
Price
$145.26
Change
-$1.67 (-1.14%)
Updated
Dec 26 closing price
Capitalization
14.48B
46 days until earnings call
Intraday BUY SELL Signals
SBFM
Price
$1.26
Change
-$0.05 (-3.82%)
Updated
Dec 26 closing price
Capitalization
6.18M
60 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

NBIX vs SBFM

Header iconNBIX vs SBFM Comparison
Open Charts NBIX vs SBFMBanner chart's image
Neurocrine Biosciences
Price$145.26
Change-$1.67 (-1.14%)
Volume$693.79K
Capitalization14.48B
Sunshine Biopharma
Price$1.26
Change-$0.05 (-3.82%)
Volume$106.39K
Capitalization6.18M
NBIX vs SBFM Comparison Chart in %
NBIX
Daily Signal:
Gain/Loss:
SBFM
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
NBIX vs. SBFM commentary
Dec 28, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NBIX is a Buy and SBFM is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 28, 2025
Stock price -- (NBIX: $145.26 vs. SBFM: $1.26)
Brand notoriety: NBIX and SBFM are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: NBIX: 65% vs. SBFM: 33%
Market capitalization -- NBIX: $14.48B vs. SBFM: $6.18M
NBIX [@Pharmaceuticals: Generic] is valued at $14.48B. SBFM’s [@Pharmaceuticals: Generic] market capitalization is $6.18M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $63.66B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.45B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NBIX’s FA Score shows that 0 FA rating(s) are green whileSBFM’s FA Score has 0 green FA rating(s).

  • NBIX’s FA Score: 0 green, 5 red.
  • SBFM’s FA Score: 0 green, 5 red.
According to our system of comparison, NBIX is a better buy in the long-term than SBFM.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NBIX’s TA Score shows that 4 TA indicator(s) are bullish while SBFM’s TA Score has 4 bullish TA indicator(s).

  • NBIX’s TA Score: 4 bullish, 4 bearish.
  • SBFM’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, NBIX is a better buy in the short-term than SBFM.

Price Growth

NBIX (@Pharmaceuticals: Generic) experienced а +0.18% price change this week, while SBFM (@Pharmaceuticals: Generic) price change was -9.35% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -0.01%. For the same industry, the average monthly price growth was +6.35%, and the average quarterly price growth was +23.01%.

Reported Earning Dates

NBIX is expected to report earnings on Feb 11, 2026.

SBFM is expected to report earnings on Feb 25, 2026.

Industries' Descriptions

@Pharmaceuticals: Generic (-0.01% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NBIX($14.5B) has a higher market cap than SBFM($6.18M). NBIX has higher P/E ratio than SBFM: NBIX (34.67) vs SBFM (0.24). NBIX YTD gains are higher at: 6.418 vs. SBFM (-58.000). NBIX has higher annual earnings (EBITDA): 613M vs. SBFM (-6.2M). NBIX has more cash in the bank: 1.12B vs. SBFM (9.31M). SBFM has less debt than NBIX: SBFM (855K) vs NBIX (428M). NBIX has higher revenues than SBFM: NBIX (2.68B) vs SBFM (37.3M).
NBIXSBFMNBIX / SBFM
Capitalization14.5B6.18M234,590%
EBITDA613M-6.2M-9,886%
Gain YTD6.418-58.000-11%
P/E Ratio34.670.2414,610%
Revenue2.68B37.3M7,193%
Total Cash1.12B9.31M11,982%
Total Debt428M855K50,058%
FUNDAMENTALS RATINGS
NBIX vs SBFM: Fundamental Ratings
NBIX
SBFM
OUTLOOK RATING
1..100
7665
VALUATION
overvalued / fair valued / undervalued
1..100
74
Overvalued
43
Fair valued
PROFIT vs RISK RATING
1..100
54100
SMR RATING
1..100
5496
PRICE GROWTH RATING
1..100
5082
P/E GROWTH RATING
1..100
5769
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SBFM's Valuation (43) in the null industry is in the same range as NBIX (74) in the Biotechnology industry. This means that SBFM’s stock grew similarly to NBIX’s over the last 12 months.

NBIX's Profit vs Risk Rating (54) in the Biotechnology industry is somewhat better than the same rating for SBFM (100) in the null industry. This means that NBIX’s stock grew somewhat faster than SBFM’s over the last 12 months.

NBIX's SMR Rating (54) in the Biotechnology industry is somewhat better than the same rating for SBFM (96) in the null industry. This means that NBIX’s stock grew somewhat faster than SBFM’s over the last 12 months.

NBIX's Price Growth Rating (50) in the Biotechnology industry is in the same range as SBFM (82) in the null industry. This means that NBIX’s stock grew similarly to SBFM’s over the last 12 months.

NBIX's P/E Growth Rating (57) in the Biotechnology industry is in the same range as SBFM (69) in the null industry. This means that NBIX’s stock grew similarly to SBFM’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NBIXSBFM
RSI
ODDS (%)
N/A
Bullish Trend 2 days ago
89%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
67%
Bullish Trend 2 days ago
85%
Momentum
ODDS (%)
Bearish Trend 2 days ago
60%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bearish Trend 2 days ago
55%
Bearish Trend 2 days ago
89%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
70%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
71%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
71%
Bullish Trend about 1 month ago
78%
Declines
ODDS (%)
Bearish Trend 2 days ago
56%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
72%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
89%
View a ticker or compare two or three
Interact to see
Advertisement
NBIX
Daily Signal:
Gain/Loss:
SBFM
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
MTZ224.400.90
+0.40%
MasTec
SXI229.440.02
+0.01%
Standex International Corp
SFBC43.61-0.14
-0.32%
Sound Financial Bancorp
NDRA5.08-0.02
-0.39%
ENDRA Life Sciences Inc
APPS5.22-0.16
-2.97%
Digital Turbine

NBIX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NBIX has been loosely correlated with TEVA. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if NBIX jumps, then TEVA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NBIX
1D Price
Change %
NBIX100%
-1.14%
TEVA - NBIX
35%
Loosely correlated
+0.47%
EOLS - NBIX
31%
Poorly correlated
+0.73%
AQST - NBIX
30%
Poorly correlated
+0.34%
ELAN - NBIX
30%
Poorly correlated
+0.98%
AMRX - NBIX
28%
Poorly correlated
+0.62%
More

SBFM and

Correlation & Price change

A.I.dvisor tells us that SBFM and ELAN have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SBFM and ELAN's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SBFM
1D Price
Change %
SBFM100%
-3.82%
ELAN - SBFM
27%
Poorly correlated
+0.98%
VTRS - SBFM
27%
Poorly correlated
+0.65%
NBIX - SBFM
27%
Poorly correlated
-1.14%
HROW - SBFM
25%
Poorly correlated
-0.14%
OGI - SBFM
25%
Poorly correlated
+1.70%
More